Current Report Filing (8-k)
September 18 2020 - 4:32PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): September 16, 2020
Commission
File No. 000-16929
Soligenix,
Inc.
(Exact
name of small business issuer as specified in its charter)
DELAWARE
|
|
41-1505029
|
(State
or other jurisdiction of
incorporation or organization)
|
|
(I.R.S.
Employer
Identification Number)
|
|
|
|
29
Emmons Drive,
Suite
B-10
Princeton,
NJ
|
|
08540
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(609)
538-8200
(Issuer’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $.001 per share
|
|
SNGX
|
|
The
Nasdaq Capital Market
|
Common
Stock Purchase Warrants
|
|
SNGXW
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.03.
|
Amendments
to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
As
described below in Item 5.07, on September 16, 2020, the stockholders of Soligenix, Inc. (the “Company”) approved
and adopted an amendment to the Second Amended and Restated Certificate of Incorporation (“Charter Amendment”), which
increased the number of authorized shares of Common Stock from 50,000,000 to 75,000,000. The Charter Amendment became
effective upon filing with the Secretary of State of the State of Delaware on September 16, 2020. A copy of the Charter Amendment
is filed herewith as Exhibit 3.1 and is incorporated herein by reference.
Item
5.07.
|
Submission
of Matters to a Vote of Security Holders.
|
On
September 16, 2020, the Company held its 2020 Annual Meeting of Stockholders, at which the following items were voted upon:
(1)
|
Election
of Directors:
|
The
following five nominees were elected as directors to serve until the 2021 Annual Meeting of Stockholders by votes as follows:
Name
|
|
For
|
|
|
Withheld
|
|
Gregg A.
Lapointe, CPA
|
|
|
6,310,341
|
|
|
|
783,593
|
|
Diane L. Parks
|
|
|
6,605,996
|
|
|
|
487,938
|
|
Robert J. Rubin, MD
|
|
|
6,602,825
|
|
|
|
491,109
|
|
Christopher J. Schaber,
PhD
|
|
|
6,266,366
|
|
|
|
827,568
|
|
Jerome B. Zeldis, MD,
PhD
|
|
|
6,471,903
|
|
|
|
622,031
|
|
There
were 14,634,578 broker non-votes in the election of directors.
(2)
|
The
approval of an amendment to the Second Amended and Restated Certificate of Incorporation, which increases the number of authorized
shares of Common Stock from 50,000,000 to 75,000,000:
|
The
proposal to approve the Charter Amendment was approved, and the votes were as follows:
For
|
|
Against
|
|
Abstain
|
16,631,587
|
|
4,842,390
|
|
254,535
|
There
were no broker non-votes on this proposal.
(3)
|
Non-binding
advisory vote on executive compensation:
|
The
proposal to approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed
in the Company’s 2020 proxy statement was approved, and the votes were as follows:
For
|
|
Against
|
|
Abstain
|
5,664,169
|
|
1,129,813
|
|
299,952
|
There
were 14,634,578 broker non-votes on this proposal.
(4)
|
Ratification
of the Appointment of Independent Registered Public Accounting Firm:
|
The
proposal to ratify the appointment of EisnerAmper, LLP as the independent registered public accounting firm of the Company for
the fiscal year ending December 31, 2020 was approved by votes as follows:
For
|
|
Against
|
|
Abstain
|
20,580,248
|
|
445,460
|
|
702,804
|
There
were no broker non-votes on this proposal.
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Soligenix,
Inc.
|
|
|
September
18, 2020
|
By:
|
/s/
Christopher J. Schaber
|
|
|
Christopher J. Schaber, Ph.D.
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
3
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Apr 2023 to Apr 2024